ChemIDplus Advanced United States National Library of Medicine Accessed on 29 Jul 2013 from http://chem.sis.nlm.nih.gov/chemidplus/chemidheavy.jsp. Note: Compound name must be entered under "Substance Identification" and then "Names and Synonyms" selected to view synonyms.
Interferon-β-1b: a review of its use in multiple sclerosis. Plosker GL CNS Drugs. 2011 Jan; 25(1):67-88. PMID: 21128695. Abstract
Serum from interferon-β-1b-treated patients with early multiple sclerosis stabilizes the blood-brain barrier in vitro. Müller M, Frese A, Nassenstein I, Hoppen M, Marziniak M, Ringelstein E B, Kim K S, Schäbitz W-R, Kraus J Mult Scler. 2012 Feb; 18(2):236-9. Epub 2011 Aug 15. PMID: 21844066. Abstract
Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. Reder AT, Ebers GC, Traboulsee A, Li D, Langdon D, Goodin DS, Bogumil T, Beckmann K, Konieczny A, Investigators of the 16-Year Long-Term Follow-Up Study Neurology. 2010 Jun 8; 74(23):1877-85. PMID: 20530324. Abstract
10 years of interferon beta-1b (Beta feron therapy. Kappos L, Hartung H-P J Neurol. 2005 Sep; 252 Suppl 3:iii1-iii2. PMID: 16170493. Abstract
Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis. Arnason BGW J Neurol. 2005 Sep; 252 Suppl 3:iii28-iii33. PMID: 16170497. Abstract
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993 Apr; 43(4):655-61. PMID: 8469318. Abstract
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Bauer L, Jakobs P, et al. Neurology. 2006 Oct 10; 67(7):1242-9. Epub 2006 Aug 16. PMID: 16914693. Abstract
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, Montanari E, Zaffaroni M, Independent Comparison of Interferon(INCOMIN) Trial Study Group Lancet. 2002 Apr 27; 359(9316):1453-60. PMID: 11988242. Abstract
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Koch-Henriksen N, Sørensen PS, Christensen T, Frederiksen J, Ravnborg M, Jensen K, Heltberg A, Kristensen O, Stenager E, Petersen T, et al. Neurology. 2006 Apr 11; 66(7):1056-60. Epub 2006 Mar 01. PMID: 16510769. Abstract
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung H-P, Jeffery D, Kappos L, Boateng F, et al. Lancet Neurol. 2009 Oct; 8(10):889-97. Epub 2009 Sep 02. PMID: 19729344. Abstract